Glucose 6-phosphate dehydrogenase (G6PD), quantitative, blood and RBC

Alphabetical Test listing

Glucose 6-phosphate dehydrogenase (G6PD), quantitative, blood and RBC-13506

Glucose 6-phosphate dehydrogenase (G6PD), quantitative, blood and RBC
Glucose 6-phosphate dehydrogenase (G6PD), quant, whole blood and RBC
G6PD, quant, blood
G6PD, quantitative, blood and RBC

Evaluate glucose 6-phosphate dehydrogenase (G6PD) deficiency.


This test may be collected M-Th only.

EDTA whole blood
8 mL (4 mL in each of two tubes)
RBC: Two 500 ┬ÁL Microtainer - Lavender (EDTA)
G6P: 1 Lavender (EDTA) or Dk green heparin (Li or Na) or 1 Yellow ACD 1(A or B)
  • Collect M - Th only
  • Immediately following collection, mix samples thoroughly by gentle inverting 8 - 10 times to prevent clotting

Lavender (EDTA), 4mL

Heparin whole blood and EDTA whole blood
ACD whole blood and EDTA whole blood

Dk green heparin (Li or Na), no gel and Lavender (EDTA), 4mL

 or  AND


Yellow ACD (A or B) and Lavender (EDTA), 4mL

 or  AND

Heparin and EDTA or ACD and EDTA - 4 mL each

Immediately following collection, mix samples thoroughly by gentle inverting 8 - 10 times to prevent clotting


Heparin whole blood and one EDTA whole blood


ACD whole blood and EDTA whole blood



Refrigerated - 72 hours


Refrigerated - 7 days



  • Hemolysis
  • Tube not filled with minimum fill volume
  • Specimen drawn in any anticoagulant other than EDTA
  •  Specimens diluted or contaminated with IV fluid
  • Clotted specimen
  • Improper labeling
  • Transfer tubes with whole blood
  • Lavender-top (EDTA) tubes received with plasma removed
  • Samples more than 72 hours old


  • Frozen specimen
  • Clotted specimen
LabCorp Burlington (001917): R-LC
Mo - Sa
2 - 4 days

Kinetic - 340 nm




Unit/trillion RBC's


Unit/trillion RBC's

0 - 30 days



31 days - 6 months



7 months - 5 years



6 - 17 years



18 - 30 years

156 - 397

155 - 399

>30 years

127 - 427

127 - 427



G6PD deficiency, an X-linked disorder, is the most common enzymatic disorder of red blood cells in humans, affecting more than 400 million people worldwide.

The clinical expression of G6PD variants encompasses a spectrum of hemolytic syndromes. Affected patients are most often asymptomatic, but many patients have episodic anemia, while a few have chronic hemolysis.
With the most prevalent G6PD variants (G6PD A- and G6PD Mediterranean), hemolysis is induced in children and adults by the sudden destruction of older, more deficient erythrocytes after exposure to drugs having a high redox potential (including the antimalarial drug primaquine and certain sulfa drugs) or to fava beans, selected infections, or metabolic abnormalities. In the neonate with G6PD deficiency, however, decreased bilirubin elimination may play an important role in the development of jaundice.
G6PD deficiency should be suspected in any subject with an episode of nonimmune hemolytic anemia, especially if occurring after drug ingestion, infection, or an episode of diabetic ketoacidosis.
G6PD hemolysis is associated with formation of Heinz bodies in peripheral red blood cells. It is the older erythrocytes that are most G6PD-deficient in affected individuals. These cells are first eliminated in a hemolytic crisis. The younger cells and reticulocytes contain more G6PD. For these reasons, after a hemolytic crisis, when only younger erythrocytes and reticulocytes are present, the G6PD values may be spuriously normal.
These "false-negative" (ie, spuriously normal or high) results are a potential concern because the most severely deficient red cells have already been removed from the circulation via hemolysis.
This problem is usually not important when testing male Caucasians but is a concern in some Caucasian females and blacks of both sexes, especially during the reticulocytosis following acute hemolysis. When a false-negative test is suspected, the best approach is to reëvaluate the patient three months after the hemolytic episode, a time at which the red cell mass will have been repopulated with red cells of all ages.
To prevent future hemolytic episodes, subjects with G6PD deficiency should avoid drugs and chemicals with oxidant potential. A partial list of safe and unsafe drugs is given in following table.
Partial List of Drugs and Chemicals in Glucose-6-Phosphate Dehydrogenase Deficiency
**Note: This is a partial list only. 
Source: Beutler E. G6PD deficiency. Blood. 1994 Dec 1; 84(11):3613-3636.
Unsafe for Class I, II, and III Variants         Safe for Class II and III Variants
Acetanilid                                                                   Acetaminophen
Dapsone                                                                      Aminopyrine
Furazolidone                                                             Ascorbic acid (except in very high doses)
Methylene blue                                                       Aspirin
Nalidixic acid                                                             Chloramphenicol
Naphthalene (mothballs, henna)                     Chloroquine
Niridazole                                                                   Colchicine
Nitrofurantoin                                                          Diphenhydramine
Phenazopyridine                                                     Isoniazid
Phenylhydrazine                                                      L-Dopa
Primaquine                                                               Menadione
Sulfacetamide                                                          Para-aminobenzoic acid
Sulfamethoxazole (Δ)                                           Phenacetin
Sulfanilamide                                                           Phenytoin
Sulfapyridine                                                            Probenecid
Thiazolesulfone                                                       Procainamide
Toluidine blue                                                          Pyrimethamine
Trinitrotoluene                                                        Quinidine
Uricase (rasburicase, pegloticase)                   Quinine
                                                                                        Vitamin K
Result 49502-8